Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HyperTargIPS-NK

Financiado

Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-t...

Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapies The HyperTargIPS-NK project aims to combine novel technologies from three research laboratories and a stem cell company to develop a revolutionary therapeutic modality for patients with devastating refractory malignancies. The tre... ver más

31/03/2026

AMNIOTICS

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

AMNIOTICS AB No se ha especificado una descripción o un objeto social para esta compañía.

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-19

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100%

4 Participantes

AMNIOTICS

805.45K€ | Lider

LUNDS UNIVERSITET

999.54K€ | Participante

MHH

989.91K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CPP2021-008350 Células CAR-NK "off-the-shelf" de próxima generación derivad... 98K€ Cerrado

CNS2023-144487 Inmunidad, infección e inmunoterapia 200K€ Cerrado

CHEMCELL Chemical Engineering of Natural Killer Cells for Cancer Immu... 150K€ Cerrado

CNS2023-145292 MODELANDO LA CARCINOGENESIS CON CELULAS PLUTIPOTENTES PARA E... 198K€ Cerrado

SynT Generation, validation and use of a synthetic reporter of CA... 150K€ Cerrado

DIN2018-009888 Inmunoterapia celular contra el cáncer: células CAR-T NKG2D... 43K€ Cerrado

Duración del proyecto: 38 meses Fecha Inicio: 2023-01-19
Fecha Fin: 2026-03-31

Líder del proyecto

AMNIOTICS AB No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Descripción del proyecto The HyperTargIPS-NK project aims to combine novel technologies from three research laboratories and a stem cell company to develop a revolutionary therapeutic modality for patients with devastating refractory malignancies. The treatment we propose is based on allogenic transplantation of induced pluripotent stem (iPS) cell-derived natural killer (NK) cells, genetically modified to a hyperactive state to ensure high potency NK cell targeting and destruction of tumor cells. CAR NK-based cancer treatment is an extremely promising new therapeutic avenue. However, the full potential of CAR NK therapies will only be achieved when an off-the-shelf product is rapidly accessible to patients in need. IPS with its unlimited expansion potential is the ideal cell source for NK-based products, however, improved efficiencies of NK cell production, suitably activated status, and resistance to immune suppression would need to be achieved. We have several breakthrough technologies to address these issues with 1) a novel iPS cell differentiation system based on our newly identified metabolic regulators that can be easily scaled to generate billions of functional NK cells, 2) identified and validated several novel and state-of-the-art CAR, non-CAR and TRUCK based regulators of NK activation to elicit the hyper activated NK cell state and prolonging NK survival, and 3) improved NK response to tumors via tumor microenvironment remodeling. We will target the NK cells towards three life-threatening cancers for which novel treatment options are urgently needed as they are considered among the most lethal cancers; i.e. Pancreatic cancer, Glioblastoma, and Acute Myeloid leukemia (AML). Our iPS culture system, NK activation systems, and gene editing systems, have already been designed towards GMP compatibility. Taken together, these advances ensure that once this study is successful, our Hyper-Targ-IPS-NK cells are poised for rapid translation towards the clinic with our industrial partner.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores